{"title": "Johnson & Johnson, AbbVie shore up Imbruvica's CLL lead with Gazyva combo win", "author": "Carly Helfand", "url": "https://www.fiercepharma.com/pharma/j-j-abbvie-shore-up-imbruvica-s-cll-lead-gazyva-combo-win", "hostname": "fiercepharma.com", "description": "Add another indication for Imbruvica in chronic lymphocytic leukemia to the list. | Add another indication for Imbruvica in chronic lymphocytic leukemia to the list. On Monday, partners AbbVie and Johnson & Johnson said the standout drug had picked up another FDA green light in the disease, this time in combination with Roche's Gazyva.", "sitename": "FiercePharma", "date": "2019-01-28", "cleaned_text": "Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Resources Podcasts Fierce Events Industry Events Webinars Whitepapers Survey Events Subscribe Subscribe Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Resources Podcasts Fierce Events Industry Events Webinars Whitepapers Survey Events Subscribe Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us "}